KC-4470

293T-BCMA Cell Line

×
Please enable JavaScript in your browser to complete this form.
52260
Home » 293T-BCMA Cell Line

Background of 293T-BCMA Cell Line

One of the biggest features of BCMA targeted therapy is that it only focuses on one disease, because BCMA is almost not expressed in other tissue cells except on the surface of mature B lymphocytes and plasma cells, but it is highly expressed in all MM cells, and plays a key role in the survival, proliferation, metastasis and drug resistance of MM cells through mediating the downstream signaling pathway. So BCMA is an ideal antigenic target for the treatment of MM.

Specifications

Catalog NumberKC-4470
Cell Line Name293T-BCMA Cell Line
Host Cell Line293T
DescriptionStable HEK293T clone expressing exogenous BCMA gene in high level
QuantityTwo vials of frozen cells (≥2-106/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% DMEM + 20% FBS + 10% DMSO
Propagation MediumDMEM + 10% FBS + 1μg/mL Puromycin
Selection MarkerPuromycin
MorphologyEpithelial
SubcultureSplit saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 105 cells/mL
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeApproximately 30 hours
Mycoplasma StatusNegative

Cell Line Generation

293T BCMA cell line was generated using a lentiviral vector expressing the BCMA sequence.

Characterization

Figure 1: Characterization of BCMA overexpression in the 293T BCMA stable clone using FACS.

Figure 2: Characterization of BCMA overexpression in the 293T BCMA stable clone using PCR sequencing.

Cell Resuscitation

1. Prewarm culture medium (DMEM supplemented with 10% FBS and 1μg/mL puromycin)in a 37°C water bath.
2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
7. Incubate the flask at 37°C, 5% CO2 incubator.
8. Split saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

1. Prepare the freezing medium (70% DMEM + 20% FBS + 10% DMSO) fresh immediately before use.
2. Keep the freezing medium on ice and label cryovials.
3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
6. Aliquot 1 mL of the cell suspension into each cryovial.
7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
8. Transfer vials to liquid nitrogen for long-term storage.

References

1. Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020 Sep 17;13(1):125. doi: 10.1186/s13045-020-00962-7. PMID: 32943087; PMCID: PMC7499842.
2. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020 Apr;34(4):985-1005. doi: 10.1038/s41375-020-0734-z. Epub 2020 Feb 13. PMID: 32055000; PMCID: PMC7214244.
3. Yang J, Zhou W, Li D, Niu T, Wang W. BCMA-targeting chimeric antigen receptorT-cell therapy for multiple myeloma. Cancer Lett. 2023 Jan 28;553:215949. doi:10.1016/j.canlet.2022.215949. Epub 2022 Oct 8. PMID: 36216149.
4. Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD Jr, Zhan F. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun.2024 Jan 19;15(1):615. doi: 10.1038/s41467-024-44873-4. PMID: 38242888; PMCID:PMC10798961.
Please enable JavaScript in your browser to complete this form.